Reviva Pharmaceuticals (NASDAQ:RVPH) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a research note released on Monday, Benzinga reports. The brokerage currently has a $20.00 price target on the stock.

Separately, Benchmark reissued a speculative buy rating and set a $17.00 price objective on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 16th.

Reviva Pharmaceuticals Stock Performance

RVPH stock opened at $3.09 on Monday. The company has a market capitalization of $86.27 million, a price-to-earnings ratio of -1.88 and a beta of -0.02. The business’s 50 day moving average price is $3.63 and its two-hundred day moving average price is $4.12. Reviva Pharmaceuticals has a fifty-two week low of $2.67 and a fifty-two week high of $9.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RVPH. Vontobel Holding Ltd. purchased a new stake in Reviva Pharmaceuticals during the 4th quarter valued at about $72,000. EMC Capital Management raised its position in Reviva Pharmaceuticals by 1,294.3% in the 3rd quarter. EMC Capital Management now owns 123,915 shares of the company’s stock worth $613,000 after buying an additional 115,028 shares during the last quarter. Finally, Armistice Capital LLC raised its position in Reviva Pharmaceuticals by 194.0% in the 4th quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock worth $9,085,000 after buying an additional 1,164,000 shares during the last quarter. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.